Key Points
- CEO Eric Lefkofsky sold 250,000 Tempus AI shares for approximately $10.5 million under a pre-arranged Rule 10b5-1 trading plan, reducing his direct stake by 55.56% to 200,000 shares.
- Tempus AI exceeded second-quarter expectations: it reported an adjusted loss of $0.04 per share versus the $0.14 estimate, while revenue increased 21.6% year over year to $382.49 million.
- Analyst sentiment remains mixed, with the stock carrying an average “Hold” rating and a $68.92 average price target; the company maintained approximately $1.6 billion in 2026 revenue guidance.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the transaction, the chief executive officer directly owned 200,000 shares of the company's stock, valued at approximately $8,412,000. The trade was a 55.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Price Performance
Shares of TEM opened at $44.29 on Friday. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The stock's fifty day moving average is $51.45 and its 200-day moving average is $52.77. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The firm has a market capitalization of $7.95 billion, a price-to-earnings ratio of -25.75 and a beta of 3.46.
Tempus AI (NASDAQ:TEM - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company's quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) earnings per share. Equities analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.
More Tempus AI News
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Q2 results exceeded expectations. Tempus reported an adjusted loss of $0.04 per share, substantially narrower than the $0.14 analyst estimate and improved from a $0.22 loss a year earlier. Revenue rose 21.6% year over year to $382.49 million, slightly above the $379.69 million consensus. Tempus AI Q2 earnings report
- Positive Sentiment: Core diagnostics growth and AI investments supported the quarter. Management said investments in artificial intelligence are driving strong growth in the company’s two largest businesses, particularly Oncology Diagnostics. The company also cited progress in data and modeling capabilities, supporting its precision-medicine strategy. Tempus Reports Second Quarter 2026 Results
- Positive Sentiment: Full-year revenue guidance remained solid. Tempus maintained or updated 2026 revenue guidance at approximately $1.6 billion, broadly in line with Wall Street expectations. The guidance reinforces investor confidence in continued top-line expansion, although it does not represent a major upside surprise. Tempus AI earnings conference call
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Freedom Capital upgraded shares of Tempus AI to a "hold" rating in a research note on Tuesday, June 30th. Needham & Company LLC restated a "buy" rating and issued a $75.00 target price on shares of Tempus AI in a research report on Monday, July 20th. Guggenheim increased their price target on Tempus AI from $60.00 to $65.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. TD Cowen reiterated a "buy" rating on shares of Tempus AI in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised Tempus AI from a "sell" rating to a "hold" rating in a research note on Saturday, July 25th. Nine equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Tempus AI has an average rating of "Hold" and an average target price of $68.92.
Check Out Our Latest Analysis on TEM
Hedge Funds Weigh In On Tempus AI
Several large investors have recently made changes to their positions in TEM. Aberdeen Group plc raised its holdings in shares of Tempus AI by 64.2% in the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company's stock worth $15,530,000 after purchasing an additional 102,878 shares in the last quarter. Pictet Asset Management Holding SA boosted its holdings in Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company's stock worth $2,948,000 after buying an additional 36,096 shares in the last quarter. Bogart Wealth LLC boosted its holdings in Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company's stock worth $3,450,000 after buying an additional 58,414 shares in the last quarter. Eagle Health Investments LP acquired a new position in Tempus AI in the first quarter worth approximately $11,588,000. Finally, Alethea Capital Management LLC acquired a new position in Tempus AI in the fourth quarter worth approximately $1,863,000. Institutional investors own 24.22% of the company's stock.
Tempus AI Company Profile
(
Get Free Report)
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company's core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
